Alx Oncology Holdings Inc Stock Price, News & Analysis

ALX Oncology (NASDAQ:ALXO) announced a significant leadership change as Dr. Barbara Klencke, a current board member, has been appointed as Interim Chief Medical Officer (CMO), replacing Dr. Alan Sandler who will return to his position on the company's Board of Directors.

Dr. Klencke brings over 30 years of experience in oncology and drug development, with notable achievements including serving as CMO at Sierra Oncology until its GSK acquisition in 2022. She will oversee the development of ALX's evorpacept and ALX2004 clinical programs, focusing on the company's CD47 blocker and EGFR-targeted antibody-drug conjugate (ADC) pipeline.

ALX Oncology (NASDAQ:ALXO), a clinical-stage biotech company focused on cancer therapies, has announced its participation in two upcoming investor conferences in September 2025. The company will attend the Cantor Global Healthcare Conference on September 3, featuring a fireside chat at 9:45 AM ET, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9.

Both events will be held in New York and will include one-on-one meetings. Webcasts of the presentations will be available on ALX Oncology's website and archived for up to 90 days.

ALX Oncology (NASDAQ:ALXO) has initiated its Phase 1 clinical trial of ALX2004, a potential first-in-class antibody-drug conjugate (ADC) targeting EGFR-expressing solid tumors. The first patient has been dosed in the open-label multicenter study (NCT07085091).

The trial will evaluate ALX2004 in patients with advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), and colorectal cancer (CRC). The study comprises Phase 1a dose escalation, dose exploration, and Phase 1b dose expansion portions.

ALX2004 features an optimized design with an affinity-tuned EGFR antibody and proprietary topoisomerase I inhibitor payload. Preclinical data has shown superior stability, dose-dependent activity, and a favorable safety profile without significant EGFR-related skin toxicity. Initial safety data is expected in the first half of 2026.

ALX Oncology (NASDAQ:ALXO) reported significant advances in its clinical programs during Q2 2025. A key highlight was the identification of CD47 expression as a predictive biomarker in HER2+ gastric cancer patients, where CD47-high patients showed a 65% objective response rate with evorpacept combination therapy versus 26% in the control group.

The company has updated its ASPEN-Breast trial design to a single-arm study incorporating CD47 biomarker strategy, with interim data expected in Q3 2026. Additionally, ALX2004, their novel ADC candidate for EGFR-expressing tumors, is set to begin patient dosing in August 2025.

Financially, ALX reported $83.5 million in cash as of June 30, 2025, extending runway into Q1 2027. Q2 net loss was $25.9 million ($0.49 per share), improved from $39.4 million in Q2 2024.

ALX Oncology (NASDAQ: ALXO), a clinical-stage biotechnology company focused on developing cancer therapies, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, after market close.

The company will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET on the same day. Investors can access the event through a webcast or by dialing 1-877-407-0752 (US) or +1-201-389-0912 (International). Presentation slides and an archived recording will be available on the company's website.

ALX Oncology (NASDAQ: ALXO), a clinical-stage biotech company focused on developing cancer therapies, has announced its participation in the upcoming Jefferies 2025 Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for Thursday, June 5, 2025, at 1:25 PM ET in New York. Investors and interested parties can access the live webcast through ALX Oncology's website investor section, with a replay available for up to 90 days after the event. The conference presentation provides an opportunity for ALX Oncology to showcase its pipeline of novel cancer therapies aimed at treating cancer and extending patient survival.

ALX Oncology (NASDAQ: ALXO) has announced details about ALX2004, their novel antibody-drug conjugate (ADC) designed to treat EGFR-expressing solid tumors. The drug has received FDA IND clearance and will begin clinical trials in mid-2025, with initial safety data expected in 1H 2026. ALX2004 features a unique design with an affinity-tuned EGFR antibody and proprietary linker-Top1i payload, engineered to maximize therapeutic effectiveness while reducing toxicity. Preclinical data shows superior stability compared to other ADCs, demonstrating dose-dependent activity across various tumors without significant EGFR-related skin toxicity. The Phase 1 trial will focus on patients with relapsed/refractory cancers, including non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinoma.

ALX Oncology (NASDAQ: ALXO) has announced a webcast event scheduled for May 20, 2025, focusing on ALX2004, their novel antibody-drug conjugate (ADC). The event will showcase ALX2004's mechanism of action, preclinical data, and clinical development strategy following FDA's IND clearance earlier this year.

ALX2004, developed in-house using the company's proprietary topoisomerase I inhibitor payload platform, is designed to target EGFR-expressing tumors. The presentation will feature key executives including CEO Jason Lettmann, CMO Alan Sandler, and VP of Antibody Technologies Marija Vrljic, who will discuss planned clinical progress and updates.

ALX Oncology (ALXO) reported Q1 2025 financial results and corporate updates. The company received FDA IND clearance for ALX2004, their novel EGFR-targeted antibody-drug conjugate, with clinical trials starting mid-2025. They're focusing on evorpacept development in combination with anti-cancer antibodies, with Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies starting mid-2025. The company won't pursue U.S. registration for gastric cancer after FDA feedback indicated accelerated approval isn't feasible. Financial highlights include cash position of $107.0 million, extending runway into Q4 2026. Q1 2025 showed reduced R&D expenses at $23.9M (down from $31.7M) and increased G&A expenses at $7.9M (up from $6.0M). Net loss improved to ($30.8M) compared to ($35.6M) in Q1 2024.